RetinAI Partners with MAXO to Advance Clinical Studies in Dry Eye Disease
RetinAI, a leader in AI-driven solutions for ophthalmology, has announced a strategic partnership with MAXO, a reading center working closely with TFS HealthScience, a globally renowned Contract Research Organization (CRO), to enhance clinical studies focusing on dry eye disease (DED). This collaboration aims to leverage advanced artificial intelligence (AI) technologies to improve the understanding and treatment of this prevalent condition.
Dry eye disease affects millions worldwide, leading to discomfort, visual disturbances, and potential damage to the ocular surface. The partnership between RetinAI and Maxo seeks to streamline clinical trials, making them more efficient and effective. By integrating RetinAI's innovative AI tools with Maxo's expertise in clinical research, the two companies aim to accelerate the development of new therapies for DED.
The collaboration will focus on utilising AI to analyse data from clinical trials, enabling researchers to identify trends and insights that may not be apparent through traditional methods. This approach is expected to enhance patient outcomes and contribute to the overall advancement of ophthalmic care.
Dr. Carlos Ciller, Chairman and CEO of Ikerian and CEO of RetinAI, expressed his enthusiasm for this collaboration: “Our work with MAXO and TFS on these significant programs underscores our commitment to advancing clinical research and clinical trials in Ophthalmology. By integrating our Discovery platform, we aim to streamline data management and facilitate operations towards better study outcomes. We are dedicated to supporting CROs and Reading Centers by providing robust, user-friendly solutions that simplify data workflows in clinical trials. This collaboration is a testament to our continuous efforts to innovate and improve operations of clinical trials with efficient, intuitive technology.”
Dr. Bassem Saleh, CEO of TFS HealthScience, stated: "This partnership with RetinAI and MAXO represents a significant advancement in our mission to deliver innovative solutions to our clients. By integrating cutting-edge AI-enabled technologies, we are not only enhancing the efficiency and accuracy of our clinical trials but also paving the way for transformative drug development. We are excited about the potential impact this collaboration will have on improving patient outcomes and advancing ophthalmology research.”
This partnership marks a significant step forward in the fight against dry eye disease, showcasing the potential of AI in transforming clinical research and patient management in ophthalmology.
